ABSTRACT
The risk of developing chronic hepatitis B virus [HBV] is 5% in general population but can reach up to 20% in HIV patients. The response rate to HBV vaccine in HIV infected patients is 23.8-56 percent. The aim of this study was to evaluate response of HIV-infected patients to 20 microg dose of recombinant HBV vaccine. In this quasi experimental study, 51 subjects, sampled through census, were HIV patients who had HBsAg negative test in HIV/AIDS counseling and care center. Patients were vaccinated with 20 microg of recombinant HBV vaccine, IM at intervals of 0, 1 and 6 months. Response to the vaccine was checked 2 months after the last injection. Data were analyzed with SPSS software, using descriptive statistics and nonparametric tests. The mean age of the patients was 33.68 +/- 8.37 years. Two patients were female [3.9%] and 49 patients were male [96.1%]. Mean of hepatitis B antibody level was 47.55 +/- 71.58 mIU/ml. The levels of antibody in different patients were as follow: 31 patients [60.8%] <10 mIU/ml and 20 patients [39.2%]> 10 mIU/ml. There was no significant correlation between antibody levels and CD4 + cell count [correlation coefficient = -0.191]. Response to hepatitis B vaccination is low in HIV infected patients. Conventional dose of HBV vaccine is not enough to get protective immunity. Therefore, two-fold dose of vaccine dose, repeat of conventional dose or increasing of interval administration of hepatitis B vaccine should be considered in future studies